30,728 Shares in Amgen Inc. $AMGN Acquired by Caldwell Trust Co

Caldwell Trust Co acquired a new stake in shares of Amgen Inc. (NASDAQ:AMGN) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 30,728 shares of the medical research company’s stock, valued at approximately $8,580,000.

Other institutional investors also recently bought and sold shares of the company. Wealth Preservation Advisors LLC purchased a new stake in Amgen during the first quarter valued at approximately $25,000. Legacy Investment Solutions LLC bought a new stake in shares of Amgen during the 2nd quarter valued at $27,000. CBIZ Investment Advisory Services LLC grew its position in shares of Amgen by 1,214.3% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 92 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 85 shares during the period. Evelyn Partners Investment Management LLP purchased a new stake in shares of Amgen in the 2nd quarter worth $32,000. Finally, Howard Hughes Medical Institute bought a new position in Amgen in the 2nd quarter worth $32,000. Institutional investors own 76.50% of the company’s stock.

Insiders Place Their Bets

In other Amgen news, EVP Murdo Gordon sold 6,879 shares of Amgen stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $336.83, for a total value of $2,317,053.57. Following the transaction, the executive vice president owned 41,923 shares in the company, valued at $14,120,924.09. The trade was a 14.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Nancy A. Grygiel sold 3,139 shares of the business’s stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the transaction, the senior vice president owned 7,225 shares of the company’s stock, valued at approximately $2,436,703.50. This trade represents a 30.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 10,908 shares of company stock worth $3,674,966 in the last three months. Corporate insiders own 0.69% of the company’s stock.

Wall Street Analysts Forecast Growth

AMGN has been the topic of a number of analyst reports. DZ Bank lifted their price objective on Amgen from $335.00 to $364.00 in a research report on Monday, November 10th. Weiss Ratings raised shares of Amgen from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, October 8th. Wells Fargo & Company upped their price target on shares of Amgen from $300.00 to $325.00 and gave the stock an “equal weight” rating in a research report on Wednesday, December 10th. Scotiabank initiated coverage on shares of Amgen in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $385.00 price objective on the stock. Finally, HSBC reaffirmed a “buy” rating and issued a $425.00 target price on shares of Amgen in a report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $332.85.

Amgen Price Performance

NASDAQ:AMGN opened at $317.74 on Monday. The firm has a market capitalization of $171.10 billion, a price-to-earnings ratio of 24.55, a PEG ratio of 2.87 and a beta of 0.45. The company has a debt-to-equity ratio of 5.45, a current ratio of 1.28 and a quick ratio of 0.99. The business has a 50 day simple moving average of $316.12 and a 200-day simple moving average of $298.92. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.38.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, November 4th. The medical research company reported $5.64 earnings per share for the quarter, topping analysts’ consensus estimates of $5.01 by $0.63. Amgen had a net margin of 19.47% and a return on equity of 162.59%. The company had revenue of $9.56 billion for the quarter, compared to analyst estimates of $8.98 billion. During the same period in the prior year, the company posted $5.58 EPS. The firm’s revenue for the quarter was up 12.4% on a year-over-year basis. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. Equities analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be paid a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 3.2%. This is a boost from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date of this dividend is Friday, February 13th. Amgen’s payout ratio is currently 73.57%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.